메뉴 건너뛰기




Volumn 1, Issue 4, 2015, Pages 528-534

Changing treatment paradigms in metastatic breast cancer: Lessons learned

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

EID: 84982938339     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1198     Document Type: Review
Times cited : (91)

References (74)
  • 1
    • 67650410937 scopus 로고    scopus 로고
    • American Cancer Society. Atlanta, GA: American Cancer Society
    • American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
    • (2014) Cancer Facts & Figures 2014
  • 2
    • 0034680102 scopus 로고    scopus 로고
    • Molecular portraits of human breast tumours
    • Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
    • (2000) Nature , vol.406 , Issue.6797 , pp. 747-752
    • Perou, C.M.1    Sørlie, T.2    Eisen, M.B.3
  • 5
    • 84921954576 scopus 로고    scopus 로고
    • Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer
    • Dalmau E, Armengol-Alonso A, Muñoz M, Seguí-Palmer MA. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. Breast. 2014;23(6):710-720.
    • (2014) Breast , vol.23 , Issue.6 , pp. 710-720
    • Dalmau, E.1    Armengol-Alonso, A.2    Muñoz, M.3    Seguí-Palmer, M.A.4
  • 7
    • 84960844558 scopus 로고    scopus 로고
    • Version 2. Accessed March 10, 2015
    • National Comprehensive Cancer Network. Breast Cancer. Version 2.2015. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed March 10, 2015.
    • (2015) Breast Cancer
  • 8
    • 51049084866 scopus 로고    scopus 로고
    • Residual risk of breast cancer recurrence 5 years after adjuvant therapy
    • Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100(16):1179-1183.
    • (2008) J Natl Cancer Inst , vol.100 , Issue.16 , pp. 1179-1183
    • Brewster, A.M.1    Hortobagyi, G.N.2    Broglio, K.R.3
  • 9
    • 84874745627 scopus 로고    scopus 로고
    • Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
    • Davies C, Pan H, Godwin J, et al; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
    • (2013) Lancet , vol.381 , Issue.9869 , pp. 805-816
    • Davies, C.1    Pan, H.2    Godwin, J.3
  • 10
    • 34247481531 scopus 로고    scopus 로고
    • Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis
    • Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2006-2007;26:87-98.
    • (2006) Breast Dis , vol.26 , pp. 87-98
    • Allan, A.L.1    Vantyghem, S.A.2    Tuck, A.B.3    Chambers, A.F.4
  • 12
    • 84888391516 scopus 로고    scopus 로고
    • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
    • Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439-1445.
    • (2013) Nat Genet , vol.45 , Issue.12 , pp. 1439-1445
    • Toy, W.1    Shen, Y.2    Won, H.3
  • 13
    • 84904794527 scopus 로고    scopus 로고
    • The PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and biomarkers
    • Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154-166.
    • (2014) Ther Adv Med Oncol , vol.6 , Issue.4 , pp. 154-166
    • Paplomata, E.1    O'Regan, R.2
  • 14
    • 84863078767 scopus 로고    scopus 로고
    • Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    • Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
    • (2012) N Engl J Med , vol.366 , Issue.6 , pp. 520-529
    • Baselga, J.1    Campone, M.2    Piccart, M.3
  • 15
    • 84872518645 scopus 로고    scopus 로고
    • Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
    • Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013;31(2):195-202.
    • (2013) J Clin Oncol , vol.31 , Issue.2 , pp. 195-202
    • Wolff, A.C.1    Lazar, A.A.2    Bondarenko, I.3
  • 16
    • 84888395367 scopus 로고    scopus 로고
    • Everolimus as treatment for breast cancer patients with bone metastases only: Results of the phase II RADAR study
    • Maass N, Harbeck N, Mundhenke C, et al; German Breast Group. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol. 2013;139(12):2047-2056.
    • (2013) J Cancer Res Clin Oncol , vol.139 , Issue.12 , pp. 2047-2056
    • Maass, N.1    Harbeck, N.2    Mundhenke, C.3
  • 17
    • 84868195516 scopus 로고    scopus 로고
    • Phase II trial of temsirolimus in patients with metastatic breast cancer
    • Fleming GF, Ma CX, Huo D, et al. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012;136(2):355-363.
    • (2012) Breast Cancer Res Treat , vol.136 , Issue.2 , pp. 355-363
    • Fleming, G.F.1    Ma, C.X.2    Huo, D.3
  • 18
    • 84950294970 scopus 로고    scopus 로고
    • The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer: Part I results
    • Krop I, Johnston S, Mayer IA, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer: part I results. 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas.
    • 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas
    • Krop, I.1    Johnston, S.2    Mayer, I.A.3
  • 19
    • 84883050535 scopus 로고    scopus 로고
    • Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): A composite, multicentre, phase 3 randomised trial
    • Johnston SR, Kilburn LS, Ellis P, et al; SoFEA investigators. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989-998.
    • (2013) Lancet Oncol , vol.14 , Issue.10 , pp. 989-998
    • Johnston, S.R.1    Kilburn, L.S.2    Ellis, P.3
  • 20
    • 84863892191 scopus 로고    scopus 로고
    • FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer
    • Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30(16):1919-1925.
    • (2012) J Clin Oncol , vol.30 , Issue.16 , pp. 1919-1925
    • Bergh, J.1    Jönsson, P.E.2    Lidbrink, E.K.3
  • 21
    • 84864512253 scopus 로고    scopus 로고
    • Combination anastrozole and fulvestrant in metastatic breast cancer
    • Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435-444.
    • (2012) N Engl J Med , vol.367 , Issue.5 , pp. 435-444
    • Mehta, R.S.1    Barlow, W.E.2    Albain, K.S.3
  • 22
    • 84892648688 scopus 로고    scopus 로고
    • Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial
    • Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337.
    • (2014) J Natl Cancer Inst , vol.106 , Issue.1
    • Di Leo, A.1    Jerusalem, G.2    Petruzelka, L.3
  • 24
    • 76749091057 scopus 로고    scopus 로고
    • Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the FIRST study
    • Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530-4535.
    • (2009) J Clin Oncol , vol.27 , Issue.27 , pp. 4530-4535
    • Robertson, J.F.1    Llombart-Cussac, A.2    Rolski, J.3
  • 25
    • 84922369296 scopus 로고    scopus 로고
    • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study
    • Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
    • (2015) Lancet Oncol , vol.16 , Issue.1 , pp. 25-35
    • Finn, R.S.1    Crown, J.P.2    Lang, I.3
  • 26
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
    • (2001) N Engl J Med , vol.344 , Issue.11 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 27
    • 84862914692 scopus 로고    scopus 로고
    • Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    • Baselga J, Cortés J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
    • (2012) N Engl J Med , vol.366 , Issue.2 , pp. 109-119
    • Baselga, J.1    Cortés, J.2    Kim, S.B.3
  • 28
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743.
    • (2006) N Engl J Med , vol.355 , Issue.26 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 29
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.
    • (2012) N Engl J Med , vol.367 , Issue.19 , pp. 1783-1791
    • Verma, S.1    Miles, D.2    Gianni, L.3
  • 30
    • 84873918443 scopus 로고    scopus 로고
    • Activating HER2 mutations in HER2 gene amplification negative breast cancer
    • Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224-237.
    • (2013) Cancer Discov , vol.3 , Issue.2 , pp. 224-237
    • Bose, R.1    Kavuri, S.M.2    Searleman, A.C.3
  • 31
    • 77957352037 scopus 로고    scopus 로고
    • PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer
    • Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177(4):1647-1656.
    • (2010) Am J Pathol , vol.177 , Issue.4 , pp. 1647-1656
    • Esteva, F.J.1    Guo, H.2    Zhang, S.3
  • 32
    • 84863116159 scopus 로고    scopus 로고
    • Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors
    • Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6):593-599.
    • (2012) J Clin Oncol , vol.30 , Issue.6 , pp. 593-599
    • Niikura, N.1    Liu, J.2    Hayashi, N.3
  • 33
    • 84887056397 scopus 로고    scopus 로고
    • A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
    • Hurvitz SA, Dalenc F, Campone M, et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013;141(3):437-446.
    • (2013) Breast Cancer Res Treat , vol.141 , Issue.3 , pp. 437-446
    • Hurvitz, S.A.1    Dalenc, F.2    Campone, M.3
  • 34
    • 84928469853 scopus 로고    scopus 로고
    • Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
    • Hurvitz SA, Andre F, Jiang Z SZ, et al Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. 2014. 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas.
    • (2014) 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas
    • Hurvitz, S.A.1    Andre, F.2    Jiang, Z.S.3
  • 35
    • 84899992665 scopus 로고    scopus 로고
    • Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial
    • André F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580-591.
    • (2014) Lancet Oncol , vol.15 , Issue.6 , pp. 580-591
    • André, F.1    O'Regan, R.2    Ozguroglu, M.3
  • 36
    • 84863715765 scopus 로고    scopus 로고
    • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    • Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133(3):1057-1065.
    • (2012) Breast Cancer Res Treat , vol.133 , Issue.3 , pp. 1057-1065
    • Lin, N.U.1    Winer, E.P.2    Wheatley, D.3
  • 37
    • 77950497981 scopus 로고    scopus 로고
    • Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
    • Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301-1307.
    • (2010) J Clin Oncol , vol.28 , Issue.8 , pp. 1301-1307
    • Burstein, H.J.1    Sun, Y.2    Dirix, L.Y.3
  • 38
    • 84919647843 scopus 로고    scopus 로고
    • A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography
    • Lee H, Zheng J, Gaddy D, et al. A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. Nanomedicine. 2015;11(1):155-165.
    • (2015) Nanomedicine , vol.11 , Issue.1 , pp. 155-165
    • Lee, H.1    Zheng, J.2    Gaddy, D.3
  • 39
    • 84892959147 scopus 로고    scopus 로고
    • The immune system and response to HER2-targeted treatment in breast cancer
    • Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2):e58-e68.
    • (2014) Lancet Oncol , vol.15 , Issue.2 , pp. e58-e68
    • Bianchini, G.1    Gianni, L.2
  • 40
    • 84907494587 scopus 로고    scopus 로고
    • Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells
    • Junttila TT, Li J, Johnston J, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014;74(19):5561-5571.
    • (2014) Cancer Res , vol.74 , Issue.19 , pp. 5561-5571
    • Junttila, T.T.1    Li, J.2    Johnston, J.3
  • 41
    • 33744803712 scopus 로고    scopus 로고
    • Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
    • Kiewe P, Hasmüller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006;12(10):3085-3091.
    • (2006) Clin Cancer Res , vol.12 , Issue.10 , pp. 3085-3091
    • Kiewe, P.1    Hasmüller, S.2    Kahlert, S.3
  • 42
    • 84901587677 scopus 로고    scopus 로고
    • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial
    • von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747-756.
    • (2014) Lancet Oncol , vol.15 , Issue.7 , pp. 747-756
    • Von Minckwitz, G.1    Schneeweiss, A.2    Loibl, S.3
  • 43
    • 84907598021 scopus 로고    scopus 로고
    • Platinum-based chemotherapy in triple-negative advanced breast cancer
    • Villarreal-Garza C, Khalaf D, Bouganim N, et al. Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat. 2014;146(3):567-572.
    • (2014) Breast Cancer Res Treat , vol.146 , Issue.3 , pp. 567-572
    • Villarreal-Garza, C.1    Khalaf, D.2    Bouganim, N.3
  • 44
    • 84934291165 scopus 로고    scopus 로고
    • The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer
    • Tutt A, Ellis P, Kilburn L, et al. The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas.
    • 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas
    • Tutt, A.1    Ellis, P.2    Kilburn, L.3
  • 45
    • 78751610848 scopus 로고    scopus 로고
    • Iniparib plus chemotherapy in metastatic triple-negative breast cancer
    • O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-214.
    • (2011) N Engl J Med , vol.364 , Issue.3 , pp. 205-214
    • O'Shaughnessy, J.1    Osborne, C.2    Pippen, J.E.3
  • 46
    • 84912105634 scopus 로고    scopus 로고
    • Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer
    • O'Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32(34):3840-3847.
    • (2014) J Clin Oncol , vol.32 , Issue.34 , pp. 3840-3847
    • O'Shaughnessy, J.1    Schwartzberg, L.2    Danso, M.A.3
  • 48
    • 84908134469 scopus 로고    scopus 로고
    • Novel treatment strategies in triple-negative breast cancer: Specific role of poly(adenosine diphosphate-ribose) polymerase inhibition
    • Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med. 2014;7:307-316.
    • (2014) Pharmgenomics Pers Med , vol.7 , pp. 307-316
    • Audeh, M.W.1
  • 49
    • 84921771510 scopus 로고    scopus 로고
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244-250.
    • (2015) J Clin Oncol , vol.33 , Issue.3 , pp. 244-250
    • Kaufman, B.1    Shapira-Frommer, R.2    Schmutzler, R.K.3
  • 50
    • 84886425456 scopus 로고    scopus 로고
    • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer
    • Gucalp A, Tolaney S, Isakoff SJ, et al; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505-5512.
    • (2013) Clin Cancer Res , vol.19 , Issue.19 , pp. 5505-5512
    • Gucalp, A.1    Tolaney, S.2    Isakoff, S.J.3
  • 51
    • 84911872687 scopus 로고    scopus 로고
    • Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer
    • Bendell J, Saleh M, Rose AA, et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2014;32(32):3619-3625.
    • (2014) J Clin Oncol , vol.32 , Issue.32 , pp. 3619-3625
    • Bendell, J.1    Saleh, M.2    Rose, A.A.3
  • 52
    • 84904740329 scopus 로고    scopus 로고
    • A systematic review of bevacizumab efficacy in breast cancer
    • Kümler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev. 2014;40(8):960-973.
    • (2014) Cancer Treat Rev , vol.40 , Issue.8 , pp. 960-973
    • Kümler, I.1    Christiansen, O.G.2    Nielsen, D.L.3
  • 53
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
    • (2007) N Engl J Med , vol.357 , Issue.26 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 54
    • 79953874259 scopus 로고    scopus 로고
    • RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    • Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252-1260.
    • (2011) J Clin Oncol , vol.29 , Issue.10 , pp. 1252-1260
    • Robert, N.J.1    Diéras, V.2    Glaspy, J.3
  • 55
    • 81155123190 scopus 로고    scopus 로고
    • RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    • Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29(32):4286-4293.
    • (2011) J Clin Oncol , vol.29 , Issue.32 , pp. 4286-4293
    • Brufsky, A.M.1    Hurvitz, S.2    Perez, E.3
  • 56
    • 84863719309 scopus 로고    scopus 로고
    • Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial
    • Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012;133(3):1067-1075.
    • (2012) Breast Cancer Res Treat , vol.133 , Issue.3 , pp. 1067-1075
    • Brufsky, A.1    Valero, V.2    Tiangco, B.3
  • 57
    • 84908229537 scopus 로고    scopus 로고
    • Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial
    • Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(12):1351-1360.
    • (2014) Lancet Oncol , vol.15 , Issue.12 , pp. 1351-1360
    • Gligorov, J.1    Doval, D.2    Bines, J.3
  • 58
    • 85010192377 scopus 로고    scopus 로고
    • Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
    • Gligorov J, Bines J, Alba E, et al. Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas.
    • 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas
    • Gligorov, J.1    Bines, J.2    Alba, E.3
  • 59
    • 85051875666 scopus 로고    scopus 로고
    • Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer (mBC)
    • Doval D, Cinieri S, Bozcuk H, et al. Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer (mBC). 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas.
    • 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas
    • Doval, D.1    Cinieri, S.2    Bozcuk, H.3
  • 60
    • 84908126746 scopus 로고    scopus 로고
    • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial
    • von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1269-1278.
    • (2014) Lancet Oncol , vol.15 , Issue.11 , pp. 1269-1278
    • Von Minckwitz, G.1    Puglisi, F.2    Cortes, J.3
  • 61
    • 85010215964 scopus 로고    scopus 로고
    • Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    • Puglisi F, Cortes J, Vrdoljak E, et al. Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas.
    • 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas
    • Puglisi, F.1    Cortes, J.2    Vrdoljak, E.3
  • 62
    • 85010212727 scopus 로고    scopus 로고
    • Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)
    • Cortes J, Vrdoljak E, Puglisi F, et al. Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC). 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas.
    • 37th Annual San Antonio Breast Cancer Symposium; December 9-14; 2014; San Antonio, Texas
    • Cortes, J.1    Vrdoljak, E.2    Puglisi, F.3
  • 63
    • 77950278598 scopus 로고    scopus 로고
    • FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    • Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085-2094.
    • (2010) Cancer Res , vol.70 , Issue.5 , pp. 2085-2094
    • Turner, N.1    Pearson, A.2    Sharpe, R.3
  • 64
    • 84925408760 scopus 로고    scopus 로고
    • Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    • Soria JC, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014;25(11):2244-2251.
    • (2014) Ann Oncol , vol.25 , Issue.11 , pp. 2244-2251
    • Soria, J.C.1    DeBraud, F.2    Bahleda, R.3
  • 65
    • 0036852241 scopus 로고    scopus 로고
    • Cancer immunoediting: From immunosurveillance to tumor escape
    • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-998.
    • (2002) Nat Immunol , vol.3 , Issue.11 , pp. 991-998
    • Dunn, G.P.1    Bruce, A.T.2    Ikeda, H.3    Old, L.J.4    Schreiber, R.D.5
  • 66
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 67
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
    • (2012) N Engl J Med , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 68
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 69
    • 84879795618 scopus 로고    scopus 로고
    • The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
    • Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667-676.
    • (2013) Breast Cancer Res Treat , vol.139 , Issue.3 , pp. 667-676
    • Muenst, S.1    Soysal, S.D.2    Gao, F.3    Obermann, E.C.4    Oertli, D.5    Gillanders, W.E.6
  • 71
    • 84896260691 scopus 로고    scopus 로고
    • The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and recommendations
    • Denicoff AM, McCaskill-Stevens W, Grubbs SS, et al. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract. 2013;9(6):267-276.
    • (2013) J Oncol Pract , vol.9 , Issue.6 , pp. 267-276
    • Denicoff, A.M.1    McCaskill-Stevens, W.2    Grubbs, S.S.3
  • 72
    • 84918500160 scopus 로고    scopus 로고
    • Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: Improved outcomes with combination chemotherapy and targeted agents
    • Ganesan P, Moulder S, Lee JJ, et al. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014;13(12):3175-3184.
    • (2014) Mol Cancer Ther , vol.13 , Issue.12 , pp. 3175-3184
    • Ganesan, P.1    Moulder, S.2    Lee, J.J.3
  • 73
    • 84856528286 scopus 로고    scopus 로고
    • Impact of genomics on personalized cancer medicine
    • Arteaga CL, Baselga J. Impact of genomics on personalized cancer medicine. Clin Cancer Res. 2012;18(3):612-618.
    • (2012) Clin Cancer Res , vol.18 , Issue.3 , pp. 612-618
    • Arteaga, C.L.1    Baselga, J.2
  • 74
    • 84858424089 scopus 로고    scopus 로고
    • Converting cancer therapies into cures: Lessons from infectious diseases
    • Glickman MS, Sawyers CL. Converting cancer therapies into cures: lessons from infectious diseases. Cell. 2012;148(6):1089-1098.
    • (2012) Cell , vol.148 , Issue.6 , pp. 1089-1098
    • Glickman, M.S.1    Sawyers, C.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.